Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
Crossref DOI link: https://doi.org/10.1186/s12885-015-1825-5
Published Online: 2015-10-27
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kim, Ki Hong
Hong, Sung Joon
Han, Kyung Seok
License valid from 2015-10-27